CTNM
Contineum Therapeutics, Inc. Class A Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$479.02M
P/E Ratio
—
EPS
$-2.17
Beta
1.39
52W High
$16.33
52W Low
$3.35
50-Day MA
$14.12
200-Day MA
$10.82
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-67.74M |
| Operating Margin | 0.00% |
| Return on Equity | -26.10% |
| Return on Assets | -17.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $6.99 |
| Price-to-Book | 1.92 |
| Price-to-Sales (TTM) | 11.15 |
| EV/Revenue | 8.25 |
| EV/EBITDA | 20.76 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $32.67M |
| Float | $25.36M |
| % Insiders | 1.00% |
| % Institutions | 90.72% |
Historical Volatility
HV 10-Day
69.72%
HV 20-Day
79.23%
HV 30-Day
73.81%
HV 60-Day
72.97%
HV Rank
31.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($22.00 target)
1
Strong Buy5
Buy1
HoldData last updated: 4/10/2026